March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
A Distinctive Anti-inflammatory Mechanism In Human Ocular Cells Associated With Mapracorat, A Novel Selective Glucocorticoid Receptor Agonist
Author Affiliations & Notes
  • Jin-Zhong Zhang
    Pharmaceutical R & D, Bausch & Lomb, Rochester, New York
  • Sherry L. Spinelli
    Department of Ophthalmology, University of Rochester School of Medicine and Dentistry, Rochester, New York
  • Xia Xi
    Department of Ophthalmology, University of Rochester School of Medicine and Dentistry, Rochester, New York
  • Steven E. Feldon
    Department of Ophthalmology, University of Rochester School of Medicine and Dentistry, Rochester, New York
  • Richard P. Phipps
    Department of Ophthalmology, University of Rochester School of Medicine and Dentistry, Rochester, New York
  • Footnotes
    Commercial Relationships  Jin-Zhong Zhang, Bausch + Lomb (E); Sherry L. Spinelli, None; Xia Xi, None; Steven E. Feldon, None; Richard P. Phipps, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2350. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jin-Zhong Zhang, Sherry L. Spinelli, Xia Xi, Steven E. Feldon, Richard P. Phipps; A Distinctive Anti-inflammatory Mechanism In Human Ocular Cells Associated With Mapracorat, A Novel Selective Glucocorticoid Receptor Agonist. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2350.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Selective glucocorticoid receptor agonists (SEGRAs) are a new therapeutic class of potent anti-inflammatory agents, structurally and functionally distinct from steroids and non-steroidal anti-inflammatory drugs (NSAIDs). Mapracorat (BOL-303242-X; ZK 245186) is a novel SEGRA under clinical evaluation for the treatment of inflammatory eye and skin diseases. Ocular inflammation is associated with increased activity of proinflammatory transcription factors, such as Nuclear Factor-kappaB (NF-ΚB). Regulation of NF-ΚB is controlled by classical and alternative pathways. Our hypothesis is that mapracorat exerts its unique effects by upregulating components of the anti-inflammatory alternative NF-ΚB pathway and by downregulating components of the classical proinflammatory NF-ΚB pathway.

Methods: : Western blotting was performed for key NF-ΚB family members, RelA (p65), RelB, Inhibitor kappa kinases (IKKs) and others, to assess the changes in protein levels associated with mapracorat in primary human ocular cell types, including corneal epithelial cells, corneal fibroblasts and conjunctival fibroblasts. A range of mapracorat doses were tested at different time points in the absence and presence of a provoking agent (IL-1β). In parallel, cells were treated with a classical steroid, dexamethasone, for comparison.

Results: : Mapracorat at low nanomolar concentrations not only increased RelB protein, but also activation of other members of the "anti-inflammatory" alternative pathway such as IKKα, following IL-1β treatment, with superior effects compared to dexamethasone. Concomitantly, there was also a reduction in the levels of phosphorylated RelA (p65), an inflammation-associated NF-ΚB family member.

Conclusions: : Data suggest that mapracorat exerts its anti-inflammatory effects in part by increasing anti-inflammatory mediators, including RelB, that are part of the alternative NF-ΚB pathway, and by decreasing classical inflammatory mediators of NF-ΚB, including RelA (p65). Upregulation of RelB and the alternative NF-ΚB pathway represents an unexpected and novel anti-inflammatory mechanism of action for mapracorat.

Keywords: inflammation • transcription factors • signal transduction: pharmacology/physiology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×